Share this article
Share this article
PALO ALTO, Calif., Feb. 2, 2021 /PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a presentation of clinical study data on its investigational therapy KSI-301 will be made at the upcoming Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition meeting.
Details of the presentation are as follows:
Title: KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstrates Extended Durability in Wet AMD and Retinal Vascular Diseases
Presenter: Diana V. Do, M.D., Professor of Ophthalmology at Byers Eye Institute, Stanford University School of Medicine, Stanford, CA
. As a warehouse manager at a Food 4 Less in Los Angeles, Norma Leiva greets delivery drivers hauling in soda and chips and oversees staff stocking shelves and helping customers. At night, she returns to the home she shares with her elderly mother-in-law, praying the coronavirus isn t traveling inside her. A medical miracle at the end of last year seemed to answer her prayers: Leiva, 51, thought she was near the front of the line to receive a vaccine, right after medical workers and people in nursing homes. Now that California has expanded eligibility to millions of older residents in a bid to accelerate the administration of the vaccines she is mystified about when it will be her turn.
HIV and COVID-19: What Do We Know Now? Advertisement
HIV and COVID-19: What Do We Know Now?
Larger studies suggest people living with HIV might have a modestly higher risk of severe COVID-19, but much remains to be learned. Advertisement
In the early days of the pandemic, POZ published a roundup of What People With HIV Need to Know About the New Coronavirus. Many HIV-positive people were concerned about their risk because immune suppression is linked to more severe COVID-19. What’s more, nearly half of people living with HIV are over 50 and many have underlying health conditions associated with worse COVID-19 outcomes.
Share this article
Share this article
SEATTLE, Jan. 29, 2021 /PRNewswire/ A paper was published today by Dr. Steven Quay, M.D., PhD., CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS), entitled, A Bayesian analysis concludes beyond a reasonable doubt that SARS-CoV-2 is not a natural zoonosis but instead is laboratory derived. The 193-page paper can be downloaded from Zenodo, a general-purpose open-access repository operated by CERN, here: https://zenodo.org/record/4477081# . A short explainer video about the paper is here: https://zenodo.org/record/4477212#.
Dr. Quay Bayesian Analysis Introduction
The purpose of the analysis was to determine the origin of SARS-CoV-2, the virus that causes COVID-19. Beginning with a likelihood of 98.2% that it was a zoonotic jump from nature with only a 1.2% probability it was a laboratory escape, twenty-six different, independent facts and evidence were examined systematically. The final conclusion is that it is a 99.8% probability SARS-